@ARTICLE{
author={Ingelman-Sundberg Magnus,Jukic Marin M,Braten Line Skute,Kringen Marianne Kristiansen,Molden Espen},
year={2024},
title={What is the Current Clinical Impact of the CYP2CTG Haplotype?},
journal={CLINICAL PHARMACOLOGY & THERAPEUTICS},
volume={115},
number={2},
pages={183-183},
document_type={Letter},
} 

@ARTICLE{
author={Braten Line Skute,Ingelman-Sundberg Magnus,Jukic Marin M,Molden Espen,Kringen Marianne Kristiansen},
year={2022},
title={Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population},
journal={CTS-CLINICAL AND TRANSLATIONAL SCIENCE},
volume={15},
number={9},
pages={2135-2145},
document_type={Article},
} 

@ARTICLE{
author={Braten Line Skute,Haslemo Tore,Jukic Marin M,Ivanov Maxim,Ingelman-Sundberg Magnus,Molden Espen,Kringen Marianne Kristiansen},
year={2021},
title={A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram},
journal={CLINICAL PHARMACOLOGY & THERAPEUTICS},
volume={110},
number={3},
pages={786-793},
document_type={Article},
} 

@ARTICLE{
author={Braten Line Skute,Haslemo Tore,Jukic Marin M,Ingelman-Sundberg Magnus,Molden Espen,Kringen Marianne Kristiansen},
year={2020},
title={Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients},
journal={NEUROPSYCHOPHARMACOLOGY},
volume={45},
number={3},
pages={570-576},
document_type={Article},
}